Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early clinical study group (ECSG)

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	85-88
Number of pages	4
Journal	Cancer Chemotherapy & Pharmacology
Volume	45
Publication status	Published - 2000

Research programs

@article{fd7e24e809e34ced8a680e69eb9920a0,

title = "Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early clinical study group (ECSG)",

author = "S Aamdal and B Lund and I Koier and M Houten and J Wanders and Jaap Verweij",

year = "2000",

language = "Undefined/Unknown",

volume = "45",

pages = "85--88",

journal = "Cancer Chemotherapy \& Pharmacology",

issn = "0344-5704",

publisher = "Springer Science+Business Media",

}

TY - JOUR

T1 - Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early clinical study group (ECSG)

AU - Aamdal, S

AU - Lund, B

AU - Koier, I

AU - Houten, M

AU - Wanders, J

AU - Verweij, Jaap

PY - 2000

Y1 - 2000

M3 - Article

SN - 0344-5704

VL - 45

SP - 85

EP - 88

JO - Cancer Chemotherapy & Pharmacology

JF - Cancer Chemotherapy & Pharmacology

ER -